Neuland Laboratories Ltd. (NEULANDLAB) AI Stock Analysis

• Market Cap: ₹157.47B
• Dividend Yield: 0.08%
• Average Volume (3M): 2.41K
• Price to Earnings (P/E): 120.0
• Beta (1Y): 0.94
• Revenue Growth: 0.34%
• EPS Growth: -14.13%
• Country: IN
• Employees: 1,643
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 37.00
• Shares Outstanding: 12,829,889
• 10 Day Avg. Volume: 1,318
• 30 Day Avg. Volume: 2,408
• PEG Ratio: -4.25
• Price to Book (P/B): 9.66
• Price to Sales (P/S): 9.98
• P/FCF Ratio: 132.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 246.06
• Revenue Forecast (FY): ₹17.64B

• Rating: 60 Neutral
• Price Target: ₹12,755.00 ▼(-16.45% Downside)
• Action: Reiterated Date: 03/14/26
• Date: Action: Reiterated 03/14/26

The score is driven primarily by solid financial performance (strong growth and balance sheet strength), partially offset by weak technical momentum (price below major DMAs with negative MACD) and an expensive valuation (very high P/E with a low dividend yield).

Positive Factors

Balance Sheet Strength

A high equity ratio and prudent leverage give Neuland durable financial flexibility to fund capex, scale manufacturing, and support long-term contracts. This stable balance sheet reduces refinancing risk and underpins multi-year supply commitments in the API/CMS business.

Operating Cash Generation

Sustained operating cash flow and multi-year free cash flow improvement indicate internal funding capacity for R&D, process development and capacity expansion. Reliable cash generation supports contract manufacturing scale-up and reduces dependence on external financing.

Revenue Growth & Margin Trends

Multi-year revenue expansion and improving gross margins signal stronger pricing power, manufacturing efficiency and portfolio mix improvement. These trends support sustainable EBITDA growth and competitiveness in the generics/API and custom manufacturing markets.

Negative Factors

Earnings Volatility

A steep negative EPS growth rate points to material volatility in net income that can stem from margin swings, one-offs or pricing pressure. Persistent EPS volatility undermines earnings predictability and complicates reinvestment and dividend planning over the medium term.

Free Cash Flow Variability

Declines in free cash flow and year-to-year variability raise concerns about working capital swings or project timing. Variable FCF can constrain funding for capex, customer-driven scale-ups, and make execution of multi-year CMS projects more capital-sensitive.

Rising Debt Trend

An increasing absolute debt level, even with currently prudent ratios, elevates leverage risk if revenue or margins falter. Higher debt can limit financial flexibility for opportunistic investments or make the company more sensitive to interest rate and covenant pressures over the medium term.

Neuland Laboratories Ltd. Business Overview & Revenue Model

Company Description

Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. The company was incorporated in 1984 and is headquartered in Hyderabad, India.

How the Company Makes Money

Neuland Laboratories primarily makes money by manufacturing and selling active pharmaceutical ingredients (APIs) and by earning service and manufacturing revenue through contract development and manufacturing arrangements. A key revenue stream is its Generic Drug Substances (GDS) business, where it produces APIs intended for off-patent/generic medicines and sells these APIs to pharmaceutical formulators; revenue is typically driven by API volumes shipped and negotiated pricing, and can vary by product mix and market demand. Another important stream is its Custom Manufacturing Solutions (CMS) business, where it provides process development, scale-up, and commercial manufacturing of APIs and intermediates for innovator and other pharmaceutical companies; in this model, the company earns through development/service fees and/or long-term supply revenue from manufacturing under customer contracts, often tied to project milestones and commercial volumes once a molecule is launched. Earnings are influenced by successful customer project progression (from development to commercial supply), utilization of manufacturing capacity, regulatory compliance for supplying to regulated markets, and the breadth and competitiveness of its API portfolio. Specific significant partnerships: null.

Neuland Laboratories Ltd. Financial Statement Overview

Summary

Strong overall fundamentals supported by solid income statement (78) and balance sheet (80) trends, including meaningful revenue growth, improving gross margins, and prudent leverage. Cash flow is positive but more variable (72), with recent free cash flow fluctuations tempering the score.

Income Statement

Neuland Laboratories has demonstrated significant revenue growth over the past five years, with a notable jump from 2020 to 2024. Margins have generally improved, particularly the gross profit margin, indicating efficient cost management. However, net profit margins have seen mixed results, indicating potential volatility in net earnings. Overall, the income statement reflects a strong growth trajectory with some fluctuations in profitability.

Balance Sheet

The company's balance sheet is robust, with a strong equity position and a healthy debt-to-equity ratio, indicating prudent financial leverage. The equity ratio is high, which showcases stability and a solid asset base. However, there is a notable increase in total debt over recent years, which could pose a risk if not managed carefully. Overall, the balance sheet suggests financial stability with controlled leverage.

Cash Flow

Neuland Laboratories has shown consistent operating cash flow, supporting its operational needs. Free cash flow has improved significantly since 2020, although there was a decrease in 2025. The operating cash flow to net income ratio suggests efficient cash generation relative to net income. However, fluctuations in free cash flow growth indicate potential variability in cash generation capacity. Overall, cash flow management appears sound but with some variability.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	15.33B	14.77B	15.59B	11.61B	9.23B	9.24B
Gross Profit	7.73B	7.26B	8.25B	5.47B	3.70B	3.63B
EBITDA	4.05B	4.20B	4.75B	2.79B	1.40B	1.63B
Net Income	2.40B	2.60B	3.00B	1.64B	638.22M	806.31M
Balance Sheet
Total Assets	25.34B	21.80B	18.33B	15.80B	13.83B	13.25B
Cash, Cash Equivalents and Short-Term Investments	1.80B	3.67B	1.03B	454.16M	84.68M	105.51M
Total Debt	2.65B	1.57B	953.90M	1.28B	2.41B	1.82B
Total Liabilities	9.14B	6.55B	5.50B	5.86B	5.43B	5.38B
Stockholders Equity	16.20B	15.25B	12.83B	9.94B	8.41B	7.86B
Cash Flow
Free Cash Flow	-2.07B	1.11B	1.18B	1.71B	-372.97M	839.65M
Operating Cash Flow	-367.47M	3.17B	2.61B	2.37B	603.89M	1.89B
Investing Cash Flow	-521.95M	-2.98B	-1.50B	-614.99M	-955.16M	-844.24M
Financing Cash Flow	-19.30M	249.61M	-692.82M	-1.36B	377.21M	-1.14B

Neuland Laboratories Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15265.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NEULANDLAB, the sentiment is Negative. The current price of 15265.6 is above the 20-day moving average (MA) of 12923.43, above the 50-day MA of 13407.49, and above the 200-day MA of 14325.73, indicating a bearish trend. The MACD of -328.83 indicates Positive momentum. The RSI at 39.46 is Neutral, neither overbought nor oversold. The STOCH value of 17.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NEULANDLAB.

Neuland Laboratories Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATCOPHARM	76 Outperform	₹168.96B	26.69	―	0.57%	-3.79%	-20.88%
GRANULES	73 Outperform	₹138.78B	24.17	―	0.24%	8.14%	5.18%
MARKSANS	71 Outperform	₹74.36B	18.03	―	0.44%	14.80%	1.35%
CAPLIPOINT	69 Neutral	₹124.23B	21.31	―	0.31%	11.41%	19.22%
NEULANDLAB	60 Neutral	₹157.47B	119.97	―	0.08%	0.34%	-14.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Neuland Laboratories Ltd. Corporate Events

Neuland Laboratories Reports Loss of Share Certificate by Investor

Neuland Laboratories Ltd. has informed the stock exchanges that a shareholder, identified under folio number 0005239, has reported the loss of a physical share certificate representing 100 shares. The company has received a request from this shareholder for issuance of a Letter of Confirmation in lieu of the lost certificate, in line with regulatory requirements, and has disclosed the matter for investor information and records.

The disclosure, made pursuant to Regulation 39(3) of the SEBI Listing Obligations and Disclosure Requirements, underscores the company’s compliance with procedural norms governing lost share certificates. While the event has no apparent impact on Neuland’s operations or financials, it reflects ongoing adherence to shareholder service protocols and transparency standards in its dealings with the exchanges and investors.

Neuland Labs Schedules Non-Deal Roadshows in Hong Kong and Singapore

Neuland Laboratories has announced a schedule of upcoming interactions with analysts and institutional investors as part of non-deal roadshows organized by B&K Securities. These meetings will include both group and one-on-one sessions in Hong Kong on March 10, 2026, followed by similar engagements in Singapore on March 11 and 12, 2026.

The roadshows are intended to facilitate direct dialogue between company management and the investment community, potentially enhancing transparency and investor understanding of the business. Neuland has noted that the schedule and participant list may change due to exigencies, underscoring the flexible nature of these investor engagement activities.

Neuland Laboratories Opens Special Window for Re-lodgement of Physical Share Transfers

Neuland Laboratories Ltd. has notified the stock exchanges that it has published newspaper advertisements regarding a special window for the re-lodgement of transfer requests for physical shares, in compliance with SEBI’s Listing Obligations and Disclosure Requirements. The move is aimed at informing and facilitating shareholders who still hold physical share certificates, underscoring the company’s efforts to align with evolving securities market regulations and to smoothen the transition and rectification process for such investors.